LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

31.25 -0.1

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

31.24

Máximo

31.27

Métricas clave
By Trading Economics
Ingresos	11M 64M
Ventas	-3.2M 149M
P/B Media del Sector	18.052 49.701
BPA	0.79
Margen de beneficios	42.663
Empleados	182
EBITDA	2M 83M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+5.89% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	281M 3.8B
Apertura anterior	31.35
Cierre anterior	31.25

Noticias sobre sentimiento de mercado

By Acuity

100%

323 / 345 Clasificación en Healthcare

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 may 2026, 16:33 UTC

Ganancias

Principales Movimientos del Mercado

Webull Shares Slide on 1Q Loss, Soaring Costs

23 may 2026, 08:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

23 may 2026, 08:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

23 may 2026, 08:00 UTC

Ganancias

AI Could Kill the Brokerage Industry's Cash Cow -- Barrons.com

23 may 2026, 05:58 UTC

Ganancias

Our Cadre Holdings Pick Has Disappointed. We're Sticking With It. -- Barrons.com

22 may 2026, 21:10 UTC

Ganancias

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 may 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 may 2026, 19:47 UTC

Ganancias

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 may 2026, 19:17 UTC

Charlas de Mercado

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 may 2026, 19:10 UTC

Charlas de Mercado

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 may 2026, 18:54 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

22 may 2026, 18:54 UTC

Charlas de Mercado

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 may 2026, 18:38 UTC

Charlas de Mercado

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 may 2026, 18:35 UTC

Adquisiciones, fusiones, absorciones

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 may 2026, 18:09 UTC

Charlas de Mercado

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 may 2026, 17:58 UTC

Charlas de Mercado

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 may 2026, 17:54 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

22 may 2026, 17:54 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 may 2026, 17:54 UTC

Charlas de Mercado

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 may 2026, 17:03 UTC

Charlas de Mercado

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 may 2026, 16:54 UTC

Charlas de Mercado

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 may 2026, 16:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

22 may 2026, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

22 may 2026, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

22 may 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 may 2026, 16:16 UTC

Charlas de Mercado

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 may 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

5.89% repunte

Estimación a 12 Meses

Media 33.1 USD 5.89%

Máximo 35 USD

Mínimo 31.5 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

323 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.